Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$181 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$-43 Mln
ROE
-0.3 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0.8
Industry P/E
--
EV/EBITDA
0.3
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-1.3
Face value
--
Shares outstanding
44,649,200
CFO
$-119.43 Mln
EBITDA
$-93.14 Mln
Net Profit
$-150.18 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Theseus Pharmaceuticals Inc (THRX)
| 0.2 | 1.8 | 17.7 | -58.5 | -- | -- | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
|---|---|---|
|
Theseus Pharmaceuticals Inc (THRX)
| -18.7 | -60.7 |
|
S&P Small-Cap 600
| 13.9 | -17.4 |
|
BSE Sensex
| 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Theseus Pharmaceuticals Inc (THRX)
|
4.1 | 181.3 | 0.0 | -55.9 | -- | -23.8 | -- | 0.8 |
| 6.5 | 28.2 | 0.6 | -74.1 | -11,456.1 | -179.7 | -- | 0.9 |
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the... treatment of gastrointestinal stromal tumors. The company also develops THE-349, a fourth-generation selective epidermal growth factor receptor inhibitor to address C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. As of February 14, 2024, Theseus Pharmaceuticals, Inc. operates as a subsidiary of Concentra Biosciences, LLC. Read more
Co-Founder & Chairman
Dr. Iain D. Dukes DPHIL, M.A.
Co-Founder & Chairman
Dr. Iain D. Dukes DPHIL, M.A.
Headquarters
Cambridge, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Theseus Pharmaceuticals Inc (THRX) is $4.06 (NASDAQ) as of 23-Feb-2024 09:30 EDT. Theseus Pharmaceuticals Inc (THRX) has given a return of -58.53% in the last 1 years.
Since, TTM earnings of Theseus Pharmaceuticals Inc (THRX) is negative, P/E ratio is not available.
The P/B ratio of Theseus Pharmaceuticals Inc (THRX) is 0.81 times as on 27-Feb-2024, a 80 discount to its peers’ median range of 3.98 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-4.09
|
0.93
|
|
2021
|
-16.66
|
1.85
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2022
|
-4.09
|
0.93
|
The 52-week high and low of Theseus Pharmaceuticals Inc (THRX) are Rs -- and Rs -- as of 05-Apr-2026.
Theseus Pharmaceuticals Inc (THRX) has a market capitalisation of $ 181 Mln as on 27-Feb-2024. As per SEBI classification, it is a Small Cap company.
Before investing in Theseus Pharmaceuticals Inc (THRX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.